Regarding the treatment, Gal-3 inhibition has shown potential as a therapeutic option in these patients, especially in HPV-driven HNSCC which presents a much higher Gal-3 expression than in HPV-non-driven HNSCC patients, due to the inhibition of this protein particularly interesting in this cancer subset [37]. The gene discussed is LGALS3; the disease is cancer.